Compare AURA & BRBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AURA | BRBI |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | United States | Brazil |
| Employees | N/A | 188 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 377.2M | 383.0M |
| IPO Year | 2021 | N/A |
| Metric | AURA | BRBI |
|---|---|---|
| Price | $6.27 | $14.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | ★ 248.5K | 2.9K |
| Earning Date | 03-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 5.09% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $17.24 |
| P/E Ratio | ★ N/A | $11.72 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.73 | $12.54 |
| 52 Week High | $7.48 | $67.01 |
| Indicator | AURA | BRBI |
|---|---|---|
| Relative Strength Index (RSI) | 53.56 | 48.02 |
| Support Level | $5.83 | $13.77 |
| Resistance Level | $6.73 | $14.34 |
| Average True Range (ATR) | 0.42 | 0.24 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 55.78 | 45.68 |
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
BRBI BR Partners SA, formerly BR Advisory Partners Participacoes SA, is engaged in investing in other companies, domestic or foreign, as a partner, quota holder, or shareholder, and management of its assets. It has a single reportable segment being investment banking services, which are administered and managed according to the products offered.